GGrantIndex
← Leaderboards

Cyrus Vaziri

Univ Of North Carolina Chapel Hill

$12,585,722
Attributed
$16,193,949
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200523
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$16,193,949 · 9

By mechanism

R01$15,613,421 · 7
R21$359,500 · 1
R29$221,028 · 1

Top collaborators

Most similar at Univ Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Dna Damage

Research focus

Dna DamagePathway InteractionsCellsCancer CellCancer TherapyMalignant NeoplasmsPreventDna BiosynthesisSignal TransductionChemotherapyResistanceBaseResponseGenomic InstabilityDna RepairUbiquitin-Protein LigaseLesionGenomeNeoplastic CellMolecularProteinsSmall MoleculeInnovationMission

Grant awards (49)

Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$463,301
R01 · FY2023 · ES · contact PI
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$391,466
R01 · FY2023 · CA · contact PI
Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis$508,083
R01 · FY2022 · CA · contact PI
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$463,301
R01 · FY2022 · ES · contact PI
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$344,451
R01 · FY2022 · CA · contact PI
Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis$518,457
R01 · FY2021 · CA · contact PI
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$463,301
R01 · FY2021 · ES · contact PI
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$402,605
R01 · FY2021 · CA · contact PI
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$80,061
R01 · FY2021 · CA · contact PI
Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis$518,457
R01 · FY2020 · CA · contact PI
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$467,927
R01 · FY2020 · ES · contact PI
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$403,864
R01 · FY2020 · CA · contact PI
Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis$502,902
R01 · FY2019 · CA · contact PI
Pathological Reprogramming of DNA Damage Signaling in Neoplastic Cells$469,870
R01 · FY2019 · ES · contact PI
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic target$413,559
R01 · FY2019 · CA · contact PI
Defining Mechanisms of Pathological Trans-Lesion Synthesis During Carcinogenesis$518,457
R01 · FY2018 · CA · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$333,000
R01 · FY2016 · ES · contact PI
Targeting the TLS DNA Damage Tolerance Pathway for Cancer Therapy$286,392
R01 · FY2016 · GM · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$333,000
R01 · FY2015 · ES · contact PI
Targeting the TLS DNA Damage Tolerance Pathway for Cancer Therapy$286,392
R01 · FY2015 · GM · contact PI
Novel Rad18 functions in Histone Modification and Regulation of Gene Expression$157,500
R21 · FY2015 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$329,670
R01 · FY2014 · ES · contact PI
Targeting the TLS DNA Damage Tolerance Pathway for Cancer Therapy$286,392
R01 · FY2014 · GM · contact PI
Novel Rad18 functions in Histone Modification and Regulation of Gene Expression$202,000
R21 · FY2014 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$326,340
R01 · FY2013 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$333,000
R01 · FY2012 · ES · contact PI
A Novel Role for the Fanconi Anemia Pathway in Replication of B[a]P-Adducted DNA$293,736
R01 · FY2012 · ES · contact PI
A Novel Role for the Fanconi Anemia Pathway in Replication of B[a]P-Adducted DNA$293,736
R01 · FY2011 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$282,104
R01 · FY2011 · ES · contact PI
A Novel Role for the Fanconi Anemia Pathway in Replication of B[a]P-Adducted DNA$296,703
R01 · FY2010 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$284,953
R01 · FY2010 · ES · contact PI
A Novel Role for the Fanconi Anemia Pathway in Replication of B[a]P-Adducted DNA$299,700
R01 · FY2009 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$276,341
R01 · FY2009 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$12,617
R01 · FY2009 · ES · contact PI
A Novel Role for the Fanconi Anemia Pathway in Replication of B[a]P-Adducted DNA$329,063
R01 · FY2008 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$316,032
R01 · FY2008 · ES · contact PI
A Novel DNA Re-replication Checkpoint$292,199
R01 · FY2008 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$329,063
R01 · FY2007 · ES · contact PI
A Novel DNA Re-replication Checkpoint$298,162
R01 · FY2007 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$315,410
R01 · FY2006 · ES · contact PI
A Novel DNA Re-replication Checkpoint$307,067
R01 · FY2006 · ES · contact PI
A Novel Carcinogen-Induced Cell Cycle Checkpoint$323,000
R01 · FY2005 · ES
A Novel DNA Re-replication Checkpoint$314,456
R01 · FY2005 · ES
A Novel DNA Re-replication Checkpoint$329,831
R01 · FY2004 · ES
A Novel Carcinogen-Induced Cell Cycle Checkpoint$323,000
R01 · FY2004 · ES
A Novel Carcinogen-Induced Cell Cycle Checkpoint$326,000
R01 · FY2003 · ES
A Novel Carcinogen-Induced Cell Cycle Checkpoint$326,000
R01 · FY2002 · ES
NOVEL CARCINOGEN INDUCED CELL CYCLE CHECKPOINT$110,514
R29 · FY2001 · ES
NOVEL CARCINOGEN INDUCED CELL CYCLE CHECKPOINT$110,514
R29 · FY2000 · ES